Canary Advisors has partnered with Engage Health and Sarepta Therapeutics to collect meaningful input from families of patients experienced with ELEVIDYS (delandistrogene moxeparvovec-rokl). This effort is intended to capture patient experiences and caregiver observations separately from those collected in the SRP-9001 clinical trials. The insights gained may be used by Sarepta to better understand the patient and caregiver experience with ELEVIDYS and provide a more holistic view of its impact. Participation involves a short online survey, a 30-minute Zoom interview and sharing supportive content (if desired). No preparation is needed.